Discount Agreements for Ranibizumab
The Techniker Krankenkasse aims to establish discount agreements for the active ingredient Ranibizumab to achieve cost-effectiveness. This concerns the biologics sector for the year 2026.
Techniker Krankenkasse
·Hamburg